Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
March 29 2024 - 8:00AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
12b-25
|
NOTIFICATION
OF LATE FILING |
SEC
FILE NUMBER |
|
001
39827
|
|
|
CUSIP
NUMBER |
|
|
92853V
106 |
(Check
One): |
☒
Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form N-SAR ☐ Form N-CSR |
For
Period Ended: December 31, 2023
☐
Transition Report on Form 10-K
☐ Transition Report on Form 20-F
☐ Transition Report on Form 11-K
☐ Transition Report on Form 10-Q
☐ Transition Report on Form N-SAR
For the Transition Period Ended: _______________
Read attached instruction sheet before preparing form. Please Print or Type.
Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:
PART
I
REGISTRANT
INFORMATION
Full
Name of Registrant |
Viveon Health Acquisition Corp. |
Former
Name if Applicable |
|
Address
of Principal Executive Office (Street and Number) |
3480
Peachtree Road NE
2nd
Floor - Suite #112
|
City,
State and Zip Code |
Atlanta,
Georgia 30326 |
PART
II
RULES
12b-25(b) AND (c)
If
the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b),
the following should be completed. (Check box if appropriate)
|
(a) |
The
reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense; |
☒ |
(b) |
The
subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or From
N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject
quarterly report of transition report on Form 10-Q, or portion thereof will be filed on or before the fifth calendar day following
the prescribed due date; and |
|
(c) |
The
accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable. |
PART
III
NARRATIVE
State
below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, N-SAR, N-CSR, or the transition report or portion thereof, could
not be filed within the prescribed time period.
Viveon
Health Acquisition Corp. (the “Company”) could not timely file its Annual Report on Form 10-K for the fiscal year ended December
31, 2023, because the financial statements could not be completed in sufficient time to solicit and obtain the necessary audit
and signatures thereto in a timely fashion prior to the due date of the report.
PART
IV
OTHER
INFORMATION
(1) |
Name
and telephone number of person to contact in regard to this notification |
Rom
Papadopoulos |
|
404 |
|
861-
5393 |
(Name) |
|
(Area
Code) |
|
(Telephone
Number) |
(2) |
Have
all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment
Company Act of 1940 during the preceding 12 months (or for such shorter) period that the registrant was required to file such reports)
been filed? If answer is no, identify report(s). |
|
☐ Yes
☒ No |
|
|
|
|
|
Viveon
Health Acquisition Corp. has not filed the following reports:
1) Quarterly Report on Form 10-Q for the quarterly period ended
September 30, 2023;
2)
Quarterly Report on Form 10-Q for the quarterly
period ended June 30, 2023; and
3)
Quarterly Report on Form 10-Q for the quarterly
period ended March 31, 2023.
|
|
|
|
|
|
|
(3) |
Is
it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be
reflected by the earnings statements to be included in the subject report or portion thereof? |
|
☐
Yes ☒ No |
|
|
|
|
|
If
so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons
why a reasonable estimate of the results cannot be made. |
|
|
Viveon
Health Acquisition Corp.
(Name
of Registrant as Specified in Charter)
Has
caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
Date:
March 29, 2024 |
By: |
/s/
Rom Papadopoulos |
|
Name: |
Rom
Papadopoulos |
|
Title: |
Chief
Financial Officer |
INSTRUCTION:
The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of
the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by
an authorized representative (other than an executive officer), evidence of the representative’s authority to sign on behalf of
the registrant shall be filed with the form.
ATTENTION
Intentional
misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).
GENERAL
INSTRUCTIONS
1. |
This
form is required by Rule 12b-25 (17 CFR 240.12b-25) of the General Rules and Regulations under the Securities Exchange Act of 1934. |
|
|
2. |
One
signed original and four conformed copies of this form and amendments thereto must be completed and filed with the Securities and
Exchange Commission, Washington, D.C. 20549, in accordance with Rule 0-3 of the General Rules and Regulations under the Act. The
information contained in or filed with the form will be made a matter of public record in the Commission files. |
|
|
3. |
A
manually signed copy of the form and amendments thereto shall be filed with each national securities exchange on which any class
of securities of the registrant is registered. |
|
|
4. |
Amendments
to the notifications must also be filed on form 12b-25 but need not restate information that has been correctly furnished. The form
shall be clearly identified as an amended notification. |
Viveon Health Acquisition (AMEX:VHAQ)
Historical Stock Chart
From Oct 2024 to Nov 2024
Viveon Health Acquisition (AMEX:VHAQ)
Historical Stock Chart
From Nov 2023 to Nov 2024